Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides

Inventors

PENAFUERTE DIAZ, Claudia Ania

Assignees

Cura Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11407814-B2

Patent

Publication Date

2022-08-09

Expiration Date


Abstract

Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFβ ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of preventing tumorigenesis and treating cancer.

Core Innovation

The invention provides multi-functional, multi-valent fusion polypeptides that combine an interleukin-2 (IL-2) polypeptide with two or more TGFβ superfamily receptor polypeptides. The disclosed fusion polypeptides include IL receptor signaling activity through an IL-2R activating component, while also providing TGFβ sequestration and/or blockade activity through soluble TGFβ receptor II (sTβRII) receptor components.

The problem addressed is pro-tumorigenic TGFβ activity that drives immunosuppression and supports tumor progression, including angiogenesis and EMT. The disclosure focuses on reducing TGFβ-mediated effects by blocking or sequestering pro-tumorigenic TGFβ isoforms, including TGFβ1 and TGFβ3, and thereby reducing suppression of immune-cell function.

In one example, bivalent FIST or bFIST fusion polypeptides are formed by fusing IL-2 or IL-15 to two or more TGFβ ligand-binding receptor polypeptides. The resulting fusion polypeptides include first and second sTβRII polypeptides, and the disclosure also provides linker options and optional pharmacokinetic modulators such as Fc or human serum albumin (HSA).

Claims Coverage

The provided independent claim covers fusion polypeptides that include an IL-2 polypeptide fused to first and second TGFβ superfamily receptor polypeptides, each defined as soluble TGFβ receptor II (sTβRII) polypeptides with specified sequence-identity thresholds. The inventive core combines immune activation via IL-2 and TGFβ ligand sequestration/blockade via dual sTβRII components, with additional refinements in the claim set.

Dual sTβRII TGFβ receptor configuration with IL-2 fusion

A fusion polypeptide comprising an IL-2 polypeptide having greater than 90% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 3, and a first and a second TGFβ superfamily receptor polypeptide, where each TGFβ superfamily receptor polypeptide comprises a soluble TGFβ receptor II polypeptide with greater than 95% sequence identity to SEQ ID NO: 8 or SEQ ID NO: 9.

IL-2 receptor-associated immune-cell activation requirement

The fusion polypeptide is defined as one that activates an immune cell expressing an IL-2 receptor.

Targeted TGFβ isoform binding by receptor polypeptides

The first and second TGFβ superfamily receptor polypeptides bind TGFβ1 polypeptide, TGFβ2 polypeptide, or TGFβ3 polypeptide.

Soluble TGFβ sequestration by dual receptor components

The first and second TGFβ superfamily receptor polypeptides each bind to and sequester soluble TGFβ.

sTβRII truncation variants

The first and/or second sTβRII polypeptide includes an N-terminal and/or C-terminal truncation compared to SEQ ID NO: 8 or SEQ ID NO: 9.

Pharmacokinetic modulation via Fc or albumin

The fusion polypeptide includes a pharmacokinetic modulator comprising either an immunoglobulin constant (Fc) region polypeptide or an albumin polypeptide.

Coverage centers on IL-2 fused to dual soluble TGFβ receptor II (sTβRII) polypeptides with specified sequence-identity thresholds, supporting IL-2 receptor-linked immune activation together with soluble TGFβ sequestration/blockade. Additional refinements focus on TGFβ isoform binding, immune-cell activation linkage, truncation variants of sTβRII, and pharmacokinetic modulation using Fc or albumin.

Stated Advantages

Reduces TGFβ1-mediated immunosuppression of T-cell and NK-cell proliferation.

Increases cytotoxicity.

Increases B-cell maturation and IFNγ.

Suppresses TGFβ1-induced EMT markers in lung cancer cells.

Provides enhanced immune activation, including IFNγ and CXCL10.

Improves binding to TGFβ1 and blocks TGFβ isoforms with picomolar potency.

Documented Applications

Cancer therapy by activating immune effector cells via IL receptor signaling while sequestering or blocking pro-tumorigenic TGFβ to reduce immunosuppression and tumor progression.

Use against solid tumors and hematologic cancers.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.